MicroRNA-451b participates in coronary heart disease by targeting VEGFA

Jie Lin; Jun Jiang; Ruifang Zhou; Xiaojie Li; Jun Ye

doi:10.1515/med-2020-0001

Article Open Access

MicroRNA-451b participates in coronary heart disease by targeting VEGFA

Jie Lin , Jun Jiang , Ruifang Zhou , Xiaojie Li and Jun Ye

Published/Copyright: December 26, 2019

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Open Medicine Volume 15 Issue 1

Abstract

Coronary artery disease (CAD) is one of the main causes of hospitalization worldwide and has high morbidity. MicroRNAs (miRNAs) play an important role in the pathogenesis of cardiovascular diseases. miR-451 is a special miRNA that is involved in many cancers’ development. At present, there is no research about miR-451 in coronary heart disease. In this study, we aimed to identify the action mechanism of miR-451 in coronary heart disease and human umbilical vein endothelial cells (HUVECs). In this study, we found that miR-451 is up-regulated in the peripheral blood of patients with coronary heart disease. Moreover, TargetScan and dual-luciferase reporter gene assay results showed that VEGFA is a direct target gene of miR-451. C (CCK-8) and flow cytometry assay results showed that miR-451 mimic significantly inhibits cell proliferation and promotes apoptosis in HUVECs. Moreover, we found that the role of miR-451 in HUVECs is associated with the PI3K-Akt-mTOR pathway. Taken together, the data indicates that miR-451 might be a novel bio-marker for coronary heart disease.

Keywords: Coronary heart disease; miR-451; VEGFA; HUVECs; PI3K-Akt-mTOR pathway

1 Introduction

Coronary artery disease (CAD) is typically caused by the development of atherosclerotic lesions and results in myocardial ischemia [1, 2]. CAD is related with inflammation and thrombosis, which can cause luminal stenosis or occlusion [3]. Although tremendous progress in the treatment of CAD has been made, it remains one of the leading causes of morbidity and mortality all over the world, causing major social and economic burdens [4, 5].

So far, many epidemiological studies have demonstrated several risk factors for CAD, including dyslipidemia, diabetes, high blood pressure, smoking, and diet [6, 7, 8]. A growing body of evidence suggest that abnormal changes in the expression of some genes in CAD play a crucial role in the pathogenesis of atherosclerosis [9, 10]. MicroRNAs, also known as miRNAs or small RNAs, are short-chain non-coding RNAs with regulatory functions that are widely found in plants and animals [11]. miRNAs can regulate protein translation by either complete or incomplete pairing with the target gene, or by inhibiting expression of downstream target proteins [12, 13]. miRNAs are involved in a variety of physiological processes including cell proliferation, apoptosis, signal transduction, differentiation, metabolism and hormone secretion, and have the potential to maintain embryonic stem cells [13]. mRNAs could regulate the growth and development of the human body and adapt to the environment. Studies have shown that miRNAs are related to the development of cancer [14]. Currently, a large amount of research on miRNAs focus on their effects on tumorigenesis, development, invasion, metastasis and other biological characteristics [15].

miR-451 is a tumor suppressor gene that plays a role in tumor suppression in a variety of cancers [16]. A previous study has found that miR-451 could inhibit hepatic tumor angiogenesis, revealing that it may be involved in the formation of blood vessels [17].

Functional damage of endothelial cells leads to atherosclerosis, but the specific function and mechanism of miR-451 in human umbilical vein endothelial cells remains unclear. Bioinformatics methods indicated that VEGFA was a direct target of miR-451b. Therefore, the aim of this study was to investigate the role of miR-451b in coronary heart disease (CHD) through exploring the role of miR-451b in human umbilical vein endothelial cells.

2 Materials and methods

2.1 Clinical samples

30 samples of peripheral blood of patients with coronary heart disease (age range, 46-59 years; male/female, 15/15), and 30 samples of peripheral blood of healthy control volunteer (age range, 45-58 years; male/female: 15/15) without coronary heart disease were collected. This study was approved by the Ethics Committee of Taizhou People’s Hospital. Written inform consent was obtained from every patient.

2.2 Detection of serum HDL, LDL, TC and TG levels

2 ml blood samples from each participant in fasting state were collected. Serum was collected by centrifuging at 3000×g for 15 min. ELISA assays were performed to detect the serum levels of HDL (Abcam), LDL (Abcam), TC (Abcam) and TG (Abcam) using kits according to the manufacturer’s protocol.

2.3 Cell culture

HUVECs were purchased from Shanghai Institute of Life Sciences, Chinese Academy of Sciences. HUVECs were cultured in routine medium 199 (Gibco) with 15% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), and endothelial cell growth supplement (Sigma) plus epidermal growth factor (EGF 10 ng/ml) in a 5% CO₂ humidified atmosphere at 37°C.

2.4 Cell transfection

HUVECs (5.0x10⁴ cells per well) were transfected with negative control miR-451b mimics (mimics NC) (Guangzhou Ribobio Co., Ltd., Guangzhou, China), miR-451b mimics (Guangzhou Ribobio Co., Ltd., Guangzhou, China), or miR-451b mimics +VEGFA plasmid (Santa Cruz, USA) for 48 h at 37°C using Lipofectamine^® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. 48 h after transfection, the transfection efficiency was detected using qRT-PCR.

2.5 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA was extracted via Trizol reagents (Invitrogen; Thermo Fisher Scientific, Inc.) from cells according to the manufacturer’s protocol. We detected the concentration of total RNA via a NanoDrop Spectrophotometer. cDNA was synthesized by using the PrimeScript Reverse Transcriptase Reagent kit (Takara Biotechnology Co., Ltd.). Then, we performed real-time fluorescent quantitative PCR to detect the expression level of miR-451b using SYBR Premix Ex Taq kit (Takara Biotechnology Co., Ltd.) according to the manufacturer’s protocol. The relative expression levels of miR-451b were compared between samples using U6 as control. The primers used were as follows:

U6, forward 5’-GCTTCGGCAGCACATATACTAAAAT-3’,

reverse 5’-CGCTTCACGAATTTGCGTGTCAT-3’;

miR-451b, forward 5’- CTGGAGAAACCGTTACCATTAC-3’;

reverse 5’-GTGCAGGGTCCGAGGT-3’. Relative expression levels of genes were calculated by the 2-ΔΔCt method [18]. All experiments were performed in triplicate.

2.6 Western blotting

Cells were solubilized in lysing buffer and proteins were extracted. The proteins were separated by 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), followed by transfer to polyvinylidenefluoride (PVDF) membrane. After blocking with 5% non-fat milk, the membrane was probed with primary antibodies: VEGFA (cat. no. Ab52917; 1:1,000; Abcam), PI3K (cat. no. 4257; 1:1,000; Cell Signaling Technology, Inc.), p-PI3K (cat. no. 17366; 1:1,000; Cell Signaling Technology, Inc.), AKT (cat. no. 4691; 1:1,000; Cell Signaling Technology, Inc.), p-AKT (cat. no. 4060; 1:1,000; Cell Signaling Technology, Inc.), mTOR (cat. no. 2983; 1:1,000; Cell Signaling Technology, Inc.), p-mTOR (cat. no. 5536; 1:1,000; Cell Signaling Technology, Inc.), and GAPDH (cat. no. 5174; 1:1,000; Cell Signaling Technology, Inc.). Then, HRP-conjugated secondary antibody (cat. no. 7074; 1:1,000; Cell Signaling Technology, Inc.) was added and membranes were incubated for a further 2 h at room temperature. GAPDH was used as the protein loading control. Signals were detected with an ECL system (Merck) according to the manufacturer’s instructions.

2.7 CCK-8 assays

We performed CCK8 assays to detect cell viability. Briefly, HUVECs were seeded onto 96-well plates at the density of 5x10³ cells/well and cultured for 12, 24 or 48 h, then 10 μl CCK-8 (Sigma-Aldrich, Merck KGaA) was added to medium. After incubation for 4 h, the absorbance was measured at a wavelength of 450 nm using a micro-plate reader.

2.8 Dual luciferase reporter assays

TargetScan (http://www.targetscan.org/vert_72/) was used to predict the potential targets of miR-451b, and the binding sites between miR-451b and VEGFA were observed. Then to confirm the binding sites between miR-451b and VEGFA, dual luciferase reporter assays were carried out. For the dual luciferase reporter assay, miR-451b mimics, the negative control of miR-451b mimics (NC), and the wild-type (WT) or mutant (Mutant) 3’-UTR of VEGFA were co-transfected into HUVECs in a 24-well plate for 48 h using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Renilla luciferase was used for normalization. Each sample was performed three times.

2.9 Flow cytometry assay

Cell apoptosis was detected by using Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit I (BD Bioscience, San Diego, CA, USA) according to the manufacturer’s protocol. Cells were harvested, centrifuged, and re-suspended in 100 μl of FITC-binding buffer. Approximately 5 μl of ready-to-use Annexin V-FITC (BD Bioscience) and 5 μl of propidium iodide (PI) were added to the mixture. Cells were incubated for 30 min in the dark at room temperature. Annexin V-FITC and PI fluorescence were assessed by BD FACSCalibur flow cytometer (BD Technologies). Data were analyzed using FlowJo software (version 7.6.1; FlowJo LLC, Ashland, OR, USA).

2.10 Statistical analysis

Experiments were repeated in triplicate. SPSS 19.0 software (SPSS, Inc, Chicago, IL, USA) was used for data analysis. Comparisons between groups were analyzed using Student’s t test or one-way analysis of variance analysis followed by Tukey’s post-hoc test. The data were expressed as the mean ± standard deviation (SD), and p<0.05 was considered as significant.

3 Results

3.1 The expression level of miR-451b in the serum of CHD patients

To detect the expression of miR-451b in the serum of CHD patients, and to explore the correlation between biochemical markers such as high-density lipoprotein, low-density lipoprotein, serum total cholesterol and triglyceride in peripheral blood and miR-451b, we collected 30 samples of peripheral blood of patients with coronary heart disease, and 30 samples of peripheral blood of healthy patients without coronary heart disease. We performed qRT-PCR to detect the relative expression of miR-451b in the serum of CHD patients and in the serum of healthy volunteers. The results showed that miR-451b was highly expressed in the serum of patients with coronary heart disease (Figure 1A). Compared with the healthy volunteers, high density lipoprotein (HDL) was down-regulated, low density lipoprotein (LDL), serum total cholesterol (TC), and triglyceride (TG) were significantly up-regulated in the serum of patients with coronary heart disease (Figure 1B-E).

Figure 1

miR-451b is up-regulated in the serum of patients with coronary heart disease.

(A) qRT-PCR assay detected the relative expression of miR-451. (B-E) ELISA assay detected the level of high density lipoprotein, low density lipoprotein, serum total cholesterol, and triglyceride in the serum of patients with coronary heart disease. **p<0.01.

3.2 VEGFA is a direct target of miR-451b

We performed bioinformatics (TargetScan) to predict the potential targets of miR-451b. Among these genes, VEGFA was identified as a potential target gene based on the predicted binding sites of miR-451b at its 3’UTR (Figure 2A). To further verify the relationship between miR-451b and VEGFA, dual-luciferase reporter gene assay was used. The results showed that miR-451b decreased the activity of the luciferase reporter fused to the 3’-UTR-WT of VEGFA but did not inhibit that of the reporter fused to the MUT version (Figure 2B). Taken together, these results showed that VEGFA is a direct target gene of miR-451b.

Figure 2

VEGFA is a direct target of miR-451b.

(A) The binding sites between miR-451b and the 3’-UTR of VEGFA. (B) Dual-luciferase reporter assay was performed to verify the binding sites between miR-451b and the 3’-UTR of VEGFA. **p<0.01.

3.3 Effect of miR-451b on proliferation and apoptosis in HUVECs

To examine the transfection efficiency of miR-451b in HUVECs, we performed qRT-PCR to detect the expression level of miR-451b. The results indicated that compared with the control group, the miR-451b mimic significantly increased the expression of miR-451b (Figure 3A) in HUVECs. In order to shed light on the function of miR-451b in HUVECs, we first investigated the effect of miR-451b on the proliferation of HUVECs. CCK-8 assay results indicated that compared with the control, miR-451b mimics could significantly inhibit the cell viability of HUVECs, while this effect was reversed by VEGFA plasmid (Figure 3B). To further determine whether miR-451b could regulate apoptosis of HUVECs, we performed flow cytometry to examine cell apoptosis. Flow cytometry analysis showed that miR-451b significantly promoted cell apoptosis; while when HUVECs were co-transfected with miR-451b mimics and VEGFA plasmid, cell apoptosis decreased (Figure 3C).

Figure 3

miR-451b inhibits cell proliferation and promotes cell apoptosis in HUVECs.

(A) qRT-PCR assay detected the relative expression of miR-451b when HUVECs were transfected with miR-451b mimics or NC mimics for 48 h. (B) CCK-8 assays were carried out to determine cell viability when the HUVECs were transfected with miR-451b mimics, or miR-451b mimics+VEGFA plasmid for 48 h. (C) Flow cytometry analysis analyzed the percentage of apoptotic cells when HUVECs were transfected with miR-451b mimics, or miR-451b mimics+VEGFA plasmid for 48 h. The cell apoptosis rate was calculated and presented. **p<0.01 vs. mimics NC; ##p<0.01 vs. miR-451b mimics.

3.4 Effect of miR-451b on PI3K-Akt-mTOR pathway

To explore the underlying mechanism of the role of miR-451b in HUVECs, we investigated the expression levels of related proteins in the PI3K-Akt-mTOR pathway. We found that miR-451b mimics decreased the protein expression of VEGFA. Western blot assays showed that miR-451b mimics decreased the protein expression levels of p-PI3K, p-AKT, p-mTOR in HUVECs. However, all these effects were reversed by the VEGFA plasmid (Figure 4).

Figure 4

miR-451b mimics inhibit the PI3K-Akt-mTOR pathway in HUVECs. After cell transfection, western blot analysis was used to detect the protein expression levels of VEGFA, PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR in HUVECs. The protein levels were quantified. **p<0.01 vs. mimics NC; ##p<0.01 vs. miR-451b mimics.

4 Discussion

In this study, we explored the expression level and underlying mechanism of miR-451b in coronary heart disease and endothelial cells in vitro. In brief, miR-451b was up-regulated in the serum of patients with coronary heart disease. Integrative bioinformatics prediction and dual-luciferase reporter assays showed that VEGFA was a target gene of miR-451b. In addition, miR-451b mimics inhibited proliferation of HUVECs and promoted cell apoptosis. VEGFA plasmid attenuated the inhibitory effect of miR-451b on HUVECs. Finally, we also found that miR-451b function in HUVECs was associated with the PI3K-Akt-mTOR pathway.

As our understanding of CAD has evolved from a focal to a systemic disease, systemic approaches to identify vulnerable patients have become preferable to the identification of local vulnerable plaques or myocardial damage [19]. Previousresearch demonstrated that miR-451 had potential activity in various cancer cells [20, 21, 22, 23]. It has been reported that miR-451 is down-regulated in human cancer and it is known as a potential tumor suppressor. It has been reported that miR-19a/19b, miR-20a, miR-26, miR-106 and miR-451 are up-regulated in vulnerable CAD patients compared to patients with stable angina or with non-cardiac chest pain [19]. Sondermeijer et al. indicated that miR-451 is enriched in the blood platelets of premature CAD patients [24].

In our study, we found that miR-451b was highly expressed in the serum of patients with coronary heart disease. However, the function and mechanism of miR-451b in human umbilical vein endothelial cells are still unclear. Therefore, in this study, we aimed to explore the role of miR-451 in human umbilical vein endothelial cells. Liu et al. reported that IL-6R is the direct target gene of miR-451. miR-451 inhibits the growth of hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway [17]. Yang et al. indicated that miR-451 suppresses glioma cell proliferation and invasion by targeting CAB39 [25]. In our study, VEGFA was identified as the target of miR-451b. Vascular endothelial growth factor (VEGF) is the most important factor for inducing endothelial cell proliferation, and angiogenesis in tumor tissues is directly related to VEGF. VEGF consists of five family members, namely VEGFA, VEGFB, VEGFC, VEGFD, and VEGFE. VEGF binds to its receptors to induce its biological effects [26].

In the present study, we found that miR-451b mimics could inhibit cell proliferation and increase cell apoptosis in HUVECs. However, the VEGFA plasmid reduced the inhibitory effect. We also demonstrated that miR-451b was related to the PI3K-Akt-mTOR pathway. Similarly, in a previous study, miRNA-451 has been found to inhibit the PI3K/AKT signaling pathway in glioma cells and directly influenced the biological behavior of glioma cells. Recent studies also demonstrated the role of miR-451 in the modulation of pro-inflammatory cytokine production (e.g., macrophage migration inhibitory factor) and the PI3K/AKT pathway [24, 27, 28].

In conclusion, miR-451b might modulate HUVEC proliferation and apoptosis through affecting the PI3K-Akt-mTOR signaling pathway by altering the expression of VEGFA, and thus participating in the occurrence and development of CHD. However, this was only an in vitro study of the role of miR-451b in CHD. The current study did not conduct an in vivo study of the effects of miR-451b in CHD. This was a limitation of our study and we will further study this in the future.

Acknowledgements

This study was funded by the Scientific Project of Taizhou (TS201730).

conflict of interest
Declaration of conflict of interest: None.

References

[1] Fan FF, Xu Q, Sun Q, Zhao SJ, Wang P, Guo XR. Assessment of the reporting quality of randomized controlled trials on treatment of coronary heart disease with traditional chinese medicine from the chinese journal of integrated traditional and Western medicine: a systematic review. PLoS One 2014;9:e8636010.1371/journal.pone.0086360Search in Google Scholar

[2] Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med 2014;76:44-5710.1097/PSY.0000000000000020Search in Google Scholar

[3] Tully PJ, Baumeister H. Collaborative care for the treatment of comorbid depression and coronary heart disease: a systematic review and meta-analysis protocol. Syst Rev 2014;3:12710.1186/2046-4053-3-127Search in Google Scholar

[4] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-212810.1016/S0140-6736(12)61728-0Search in Google Scholar

[5] Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011;18:351-35810.5551/jat.7591Search in Google Scholar PubMed

[6] Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 2017;18:331-34410.1038/nrg.2016.160Search in Google Scholar PubMed PubMed Central

[7] Srivastava RAK. Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem 2018;440:167-18710.1007/s11010-017-3165-zSearch in Google Scholar PubMed

[8] Souza PAL, Marcadenti A, Portal VL. Effects of Olive Oil Phenolic Compounds on Inflammation in the Prevention and Treatment of Coronary Artery Disease. Nutrients 2017;910.3390/nu9101087Search in Google Scholar PubMed PubMed Central

[9] Kondkar AA, Abu-Amero KK. Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases. Biomed Res Int 2015;2015:82182310.1155/2015/821823Search in Google Scholar PubMed PubMed Central

[10] Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010;391:73-7710.1016/j.bbrc.2009.11.005Search in Google Scholar PubMed

[11] Ambros V. The functions of animal microRNAs. Nature 2004;431:350-35510.1038/nature02871Search in Google Scholar PubMed

[12] Li Z, Qin T, Wang K, Hackenberg M, Yan J, Gao Y, et al. Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid. BMC Genomics 2015;16:36510.1186/s12864-015-1516-2Search in Google Scholar PubMed PubMed Central

[13] Ameres SL, Zamore PD. Diversifying microRNA sequence and function.Nat Rev Mol Cell Biol 2013;14:475-48810.1038/nrm3611Search in Google Scholar PubMed

[14] Ranganathan K, Sivasankar V. MicroRNAs - Biology and clinical applications. J Oral Maxillofac Pathol 2014;18:229-23410.4103/0973-029X.140762Search in Google Scholar PubMed PubMed Central

[15] Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009;27:549-55510.1038/nbt.1543Search in Google Scholar PubMed PubMed Central

[16] Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res 2010;1359:14-2110.1016/j.brainres.2010.08.074Search in Google Scholar PubMed

[17] Liu X, Zhang A, Xiang J, Lv Y, Zhang X. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep 2016;36:1385-139210.3892/or.2016.4971Search in Google Scholar PubMed

[18] Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 25:402-408,200110.1006/meth.2001.1262Search in Google Scholar PubMed

[19] Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One 2013;8:e8073810.1371/journal.pone.0080738Search in Google Scholar PubMed PubMed Central

[20] Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011;29:1661-167110.1002/stem.741Search in Google Scholar PubMed

[21] Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644-265810.1038/onc.2010.642Search in Google Scholar PubMed

[22] Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011;30:2010.1186/1756-9966-30-20Search in Google Scholar PubMed PubMed Central

[23] Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008;7:215 2-215910.1158/1535-7163.MCT-08-0021Search in Google Scholar PubMed

[24] Sondermeijer BM, Bakker A, Halliani A, de Ronde MW, Marquart AA, Tijsen AJ, et al. Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*.PLoS One 2011;6:e2594610.1371/journal.pone.0025946Search in Google Scholar PubMed PubMed Central

[25] Nan Y, Guo H, Guo L, Wang L, Ren B, Yu K, et al. MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1alpha/VEGF Signaling Pathway by Targeting CAB39. Hum Gene Ther Clin Dev 2018;29:156-16610.1089/humc.2018.133Search in Google Scholar PubMed

[26] Wang Y, Zhang F, Wang J, Hu L, Jiang F, Chen J, et al. lncRNA LOC100132354 promotes angiogenesis through VEGFA/VEGFR2 signaling pathway in lung adenocarcinoma.Cancer Manag Res 2018;10:4257-426610.2147/CMAR.S177327Search in Google Scholar PubMed PubMed Central

[27] Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009;15:2281-229010.1158/1078-0432.CCR-08-1818Search in Google Scholar PubMed

[28] Tian Y, Nan Y, Han L, Zhang A, Wang G, Jia Z, et al. MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma. Int J Oncol 2012;40:1105-111Search in Google Scholar

Received: 2019-05-16

Accepted: 2019-10-24

Published Online: 2019-12-26

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

https://doi.org/10.1515/med-2020-0001

Keywords for this article

Coronary heart disease; miR-451; VEGFA; HUVECs; PI3K-Akt-mTOR pathway

Creative Commons

BY 4.0